Implications for Guideline Developers/Users RE-AIM framework is a useful tool to evaluate the effect of using guidelines and develop strategies to disseminate them.

**P282** MANAGEMENT OF PATIENTS WITH BIPOLAR DISORDER: AN ADAPTED CLINICAL PRACTICE GUIDELINE FROM KING SAUD UNIVERSITY, KING KHALID UNIVERSITY HOSPITAL, CLINICAL PRACTICE GUIDELINES COMMITTEE, FACULTY OF MEDICINE, DEPARTMENT OF PSYCHIATRY

**Objectives** Adaptation of CPGs for Treatment of Bipolar disorder in King Khalid University Hospital, Psychiatry Department Methods The ADAPTE process for CPGs adaptation. Results: the final decision of the panel after full assessments of 3 source CPGs was full acceptance (adoption) of the Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder (updated 2009).

**Results** Examples of Recommendations Lithium, valproate, and several atypical antipsychotics monotherapy is recommended to be used as first line treatments for acute mania, combination pharmacology with antipsychotics and mood stabiliser can be used as first line option. Paliperidone monotherapy and asenapine alone or in combination with lithium or divalprox can be used as a second line treatment; tamoxfen is suggested as a third line augmentation option. For the Management of bipolar depression, lithium, lamotrigine, and quetiapine monotherapy, olanzapine plus selective serotonin reuptake inhibitor (SSRI), and lithium or divalprox plus SSRI bupropion are first-line options. Adjutitive modafinil is recommended as a second-line option. lithium, lamotrigine, valproate and olanzapine are first-line options for maintenance treatment of bipolar disorder.

**Conclusion** New data support the use of quetiapine monotherapy and adjunctive therapy for the prevention of manic and depressive events, aripiprazole monotherapy for the prevention of manic events, and risperidone long-acting injection monotherapy and adjunctive therapy, and adjunctive ziprasidone for the prevention of mood events.

**Background** Intravenous therapy is one of the most frequently used interventions in health care, with increasing complexity and duration of treatments. A clinical practice guideline (CPG) on this topic was developed within the framework of the Spanish programme (National Health System) aimed to provide recommendations on intravenous therapy best practice.

**Objective** To describe CPG development process, considering methodological issues, such as updating and adapting existing guidelines and expert inputs.

**Methods** Using the GRADE approach, an evidence synthesis was developed for each clinical question, including adoption or update of valid recommendations from selected guidelines. Expert panel followed methodology proposed by Jaescke et al with predefined consensus criteria to categorise recommendations.

**Results** After assessment with AGREE II instrument, 3 guidelines were considered highly recommended and selected for adaptation/updating. Evidence synthesis and recommendations for each 63 initial clinical question were drafted and sent to the expert panel who voted individually. Areas of disagreement were identified and discussed in a face-to-face meeting. After the second voting round 55 recommendations remained, of which 27 were rated as strong, 12 as weak and 14 as good practice recommendations. Six of them were adopted/updated from previous guidelines. In 2 cases there was no agreement in the panel and no recommendation was issued.

**Discussion** GRADE proved to be a useful method to develop a complex guideline, incorporating evidence from previous guidelines and expert opinion. The method was well accepted and followed by the panel and improved the elaboration of recommendations.